Works matching DE "PROGRAMMED death-ligand 1"

Results: 3656

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.

Published in:

Indian Journal of Pharmacology, 2022, v. 54, n. 3, p. 183, doi. 10.4103/ijp.ijp_1089_20

By:

Deepak, H;
Prince, Sabina;
Deshpande, Pratima

Publication type:

Article

PD-L1 importance in malignancies comprehensive insights into the role of PD-L1 in malignancies: from molecular mechanisms to therapeutic opportunities.

Published in:

Clinical & Experimental Medicine, 2025, v. 25, n. 1, p. 1, doi. 10.1007/s10238-025-01641-y

By:

Soltani, Mojdeh;
Abbaszadeh, Mohammad;
Fouladseresht, Hamed;
Sullman, Mark J. M.;
Eskandari, Nahid

Publication type:

Article

Decreased expression of programmed death-1 on CD8+ effector memory T lymphocytes correlates with the pathogenesis of type 1 diabetes.

Published in:

Acta Diabetologica, 2021, v. 58, n. 9, p. 1239, doi. 10.1007/s00592-021-01711-z

By:

Shan, Yimei;
Kong, Yinghong;
Zhou, Yan;
Guo, Jingjing;
Shi, Qiyun;
Li, Sicheng;
Guo, Heming;
Huang, Yiting;
Ding, Sisi;
Liu, Cuiping;
Cao, Lei;
Huang, Yun;
Fang, Chen;
Hu, Ji

Publication type:

Article

Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection.

Published in:

Digestive Diseases, 2024, v. 42, n. 1, p. 53, doi. 10.1159/000534535

By:

Su, Menghan;
Ye, Ting;
Wu, Wei;
Shu, Zheyue;
Xia, Qi

Publication type:

Article

Dynamics of Soluble Forms of the Immune Checkpoint Components PD-1/PD-L1/B7-H3, CD314/ULBP1, and HLA-G in Peripheral Blood of Melanoma Patients Receiving Blockers of Programmed Cell Death Protein PD-1.

Published in:

Bulletin of Experimental Biology & Medicine, 2023, v. 175, n. 4, p. 481, doi. 10.1007/s10517-023-05891-2

By:

Gershtein, E. S.;
Mochalova, A. S.;
Korotkova, E. A.;
Samoilova, E. V.;
Vashketova, O. I.;
Kuz'min, Yu.B.;
Sokolov, N. Yu.;
Kushlinskii, N. E.

Publication type:

Article

Expression of Inhibitory Molecules (Arginase-1, IDO, and PD-L1) by Myeloid-Derived Suppressor Cells in Multiple Myeloma Patients in Remission.

Published in:

Bulletin of Experimental Biology & Medicine, 2022, v. 174, n. 1, p. 71, doi. 10.1007/s10517-022-05651-8

By:

Tyrinova, T. V.;
Batorov, E. V.;
Aristova, T. A.;
Ushakova, G. Yu.;
Sizikova, S. A.;
Denisova, V. V.;
Ostanin, A. A.;
Chernykh, E. R.

Publication type:

Article

Expression and Content of Protein LC3B in Gastric Cancer Tissue, Relationship with Expression of mTOR, AMPK in Gastric Cancer Tissue and HER2 and PD-L1 Status of the Tumor.

Published in:

Bulletin of Experimental Biology & Medicine, 2021, v. 172, n. 2, p. 202, doi. 10.1007/s10517-021-05376-0

By:

Spirina, L. V.;
Avgustinovich, A. V.;
Afanas'ev, S. G.;
Volkov, M. Yu.;
Kondakova, I. V.

Publication type:

Article

AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.

Published in:

Bulletin of Experimental Biology & Medicine, 2020, v. 170, n. 1, p. 75, doi. 10.1007/s10517-020-05007-0

By:

Spirina, L. V.;
Avgustinovich, A. V.;
Afanas'ev, S. G.;
Kondakova, I. V.;
Volkov, M. Yu.;
Dobrodeev, A. Yu.;
Boronkina, A. I.

Publication type:

Article

Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma.

Published in:

Bulletin of Experimental Biology & Medicine, 2020, v. 169, n. 3, p. 378, doi. 10.1007/s10517-020-04891-w

By:

Safonova, E. A.;
Lopatina, K. A.;
Razina, T. G.;
Zueva, E. P.;
Gur'ev, A. M.;
Belousov, M. V.

Publication type:

Article

Clinicopathological Significance of Programed Death-Ligand-1(PD-L1) and Proliferation Cell Nuclear Antige(PCNA)Expression in Prostatic Carcinoma; an Immunohistochemical Study.

Published in:

Zagazig University Medical Journal, 2023, v. 29, n. 1, p. 229, doi. 10.21608/zumj.2022.105446.2408

By:

Abdelbary, Abeer M.;
Hafez, Abeer;
Refaat, Mohammed;
Elsebai, Eman A.

Publication type:

Article

Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma.

Published in:

Brain Communications, 2024, v. 6, n. 6, p. 1, doi. 10.1093/braincomms/fcae400

By:

Gregory, Grace E;
Haley, Michael J;
Jones, Adam P;
Hannan, Cathal J;
Evans, D Gareth;
King, Andrew T;
Paszek, Pawel;
Pathmanaban, Omar N;
Couper, Kevin N;
Brough, David

Publication type:

Article

Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays.

Published in:

NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00442-4

By:

Wang, Danyi;
Elenbaas, Brian;
Murugesan, Karthikeyan;
Shah, Kunal;
Montesion, Meagan;
Gounaris, Ioannis;
Scheuenpflug, Juergen;
Locatelli, Giuseppe;
Feng, Zheng

Publication type:

Article

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy.

Published in:

NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00443-3

By:

Li, Anlin;
Luo, Linfeng;
Du, Wei;
Yu, Zhixin;
He, Lina;
Fu, Sha;
Wang, Yuanyuan;
Zhou, Yixin;
Yang, Chunlong;
Yang, Yunpeng;
Fang, Wenfeng;
Zhang, Li;
Hong, Shaodong

Publication type:

Article

Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition.

Published in:

NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00405-9

By:

Wang, Hanwen;
Arulraj, Theinmozhi;
Kimko, Holly;
Popel, Aleksander S.

Publication type:

Article

Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns.

Published in:

NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00287-3

By:

Yu, Zi-Li;
Liu, Jin-Yuan;
Chen, Gang

Publication type:

Article

A lipid/PLGA nanocomplex to reshape tumor immune microenvironment for colon cancer therapy.

Published in:

Regenerative Biomaterials, 2024, v. 11, p. 1, doi. 10.1093/rb/rbae036

By:

Zhang, Nan;
Sun, Qiqi;
Li, Junhua;
Li, Jing;
Tang, Lei;
Zhao, Quan;
Pu, Yuji;
Liang, Gaofeng;
He, Bin;
Gao, Wenxia;
Chen, Jianlin

Publication type:

Article

Low CD86 expression is a predictive biomarker for clinical response to the therapeutic human papillomavirus vaccine IGMKK16E7: results of a post hoc analysis.

Published in:

JNCI Cancer Spectrum, 2024, v. 8, n. 6, p. 1, doi. 10.1093/jncics/pkae091

By:

Ando, Hanano;
Katoh, Yuki;
Kobayashi, Osamu;
Ikeda, Yuji;
Yahata, Hideaki;
Iwata, Takashi;
Satoh, Toyomi;
Akiyama, Azusa;
Maeda, Daichi;
Hori-Hirose, Yumiko;
Uemura, Yukari;
Nakayama-Hosoya, Kaori;
Katoh, Kanoko;
Nakajima, Takahiro;
Taguchi, Ayumi;
Komatsu, Atsushi;
Kamata, Saki;
Tomita, Naoko;
Kato, Kiyoko;
Aoki, Daisuke

Publication type:

Article

Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.

Published in:

Therapeutic Advances in Vaccines & Immunotherapy, 2024, v. 12, p. 1, doi. 10.1177/25151355241288453

By:

Kamali, Ali N.;
Hamedifar, Haleh;
Eisenhut, Michael;
Bautista, Jose M.

Publication type:

Article

1,25(OH)<sub>2</sub>D<sub>3</sub>-treated mouse bone marrow-derived dendritic cells alleviate autoimmune hepatitis in mice by improving TFR/TFH imbalance.

Published in:

Immunopharmacology & Immunotoxicology, 2025, v. 47, n. 1, p. 59, doi. 10.1080/08923973.2024.2435314

By:

Dai, Juan;
Song, Jianguo;
Chen, Xueping;
Ding, Fei;
Ding, Yanbo;
Ma, Liang;
Zhang, Liwen

Publication type:

Article

Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression.

Published in:

Immunopharmacology & Immunotoxicology, 2024, v. 46, n. 3, p. 417, doi. 10.1080/08923973.2024.2347315

By:

Yin, Chaoyun;
Pa, Yani;
Li, Guangyu;
Chen, Qiang;
Wang, Xizu;
He, Xijun;
Zhou, Huangao

Publication type:

Article

Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1.

Published in:

Immunopharmacology & Immunotoxicology, 2021, v. 43, n. 4, p. 443, doi. 10.1080/08923973.2021.1936013

By:

Liu, Wei;
Chen, Han;
Wang, Dongsheng

Publication type:

Article

DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy.

Published in:

Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-02027-x

By:

Choi, Seong Hee;
Mani, Muralidharan;
Kim, Jeonghwan;
Cho, Wha Ja;
Martin, Thomas F. J.;
Kim, Jee Hyun;
Chu, Hun Su;
Jeong, Won Jin;
Won, Young-Wook;
Lee, Byung Ju;
Ahn, Byungyong;
Kim, Junil;
Jeon, Do Yong;
Park, Jeong Woo

Publication type:

Article

NUP43 promotes PD-L1/nPD-L1/PD-L1 feedback loop via TM4SF1/JAK/STAT3 pathway in colorectal cancer progression and metastatsis.

Published in:

Cell Death Discovery, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41420-024-02025-z

By:

Wu, Fan;
Sun, Guoqiang;
Nai, Yongjun;
Shi, Xuesong;
Ma, Yong;
Cao, Hongyong

Publication type:

Article

Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.

Published in:

Turkish Journal of Medical Sciences, 2024, v. 54, n. 4, p. 735, doi. 10.55730/1300-0144.5843

By:

SAYGIN, İsmail;
ÇAKIR, Emel;
KAZAZ, Seher Nazlı;
GÜVERCİN, Ali Rıza;
EYÜPOĞLU, İlker;
USTAOĞLU, Müşerref Müge

Publication type:

Article

Role of PD-1/PD-L1-mediated tumour immune escape mechanism and microsatellite instability in the BCG failure of high-grade urothelial carcinomas.

Published in:

Turkish Journal of Medical Sciences, 2022, v. 52, n. 6, p. 1802, doi. 10.55730/1300-0144.5526

By:

SALMAN, Fadime Gül;
KANKAYA, Duygu;
ÖZAKINCI, Hilal;
ŞAHİN, Yasemin;
KUBİLAY, Eralp;
SÜER, Evren;
HAYME, Serhat;
BALTACI, Sümer

Publication type:

Article

The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients.

Published in:

Turkish Journal of Medical Sciences, 2022, v. 52, n. 4, p. 1050, doi. 10.55730/1300-0144.5407

By:

ANCIN, Burcu;
ÖZERCAN, Mesut Melih;
YILMAZ, Yiğit;
UYSAL, Serkan;
KUMBASAR, Ulaş;
SARIBAŞ, Zeynep;
DİKMEN, Erkan;
DOĞAN, Rıza;
DEMİRCİN, Metin

Publication type:

Article

PD-L1 and EBV LMP1 expressions in classic Hodgkin lymphomas and its correlation with clinicopathological parameters and prognosis.

Published in:

Turkish Journal of Medical Sciences, 2022, v. 52, n. 4, p. 1013, doi. 10.55730/1300-0144.5403

By:

ÖZDEMİR, Süleyman;
TON, Özlem;
KABUKCUOĞLU, Fevziye

Publication type:

Article

The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?

Published in:

Turkish Journal of Medical Sciences, 2021, v. 51, n. 1, p. 204, doi. 10.3906/sag-2004-61

By:

BULUTAY, Pınar;
FIRAT, Pınar;
ZEREN, Handan;
ERUS, Suat;
TANJU, Serhan;
DİLEGE, Şükrü

Publication type:

Article

PROGNOSTIC ROLE OF FILGRASTIM IN THE EFFECTIVENESS OF PD-1/PD-L1 INHIBITORS IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER.

Published in:

Farmacia, 2023, v. 71, n. 3, p. 556, doi. 10.31925/farmacia.2023.3.14

By:

MARIN POZO, JUAN FRANCISCO;
MUÑOZ CID, CARMEN LUCIA;
CLARAMUNT GARCIA, RAQUEL;
MARIN CABA, ELVIRA;
ORTEGA GRANADOS, ANA LAURA

Publication type:

Article

THE CHALLENGES OF USING PD-L1 AS A PREDICTIVE BIOMARKER AND THE THERAPEUTIC APPROACH IN NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY.

Published in:

Farmacia, 2020, v. 68, n. 3, p. 390, doi. 10.31925/farmacia.2020.3.3

By:

PĂTCAS, ADELA;
MOGOSAN, CRISTINA;
ALEXESCU, TEODORA GABRIELA;
BORDEA, IOANA ROXANA;
BUZOIANU, ANCA DANA;
TODEA, DOINA ADINA

Publication type:

Article

Peptides-functionalized gold nanostars enhanced degradation of PD-L1 for improved prostate cancer immunotherapy.

Published in:

Journal of Biomaterials Applications, 2025, v. 39, n. 10, p. 1188, doi. 10.1177/08853282251319473

By:

Tao, Liangjun;
Zhang, Yifei;
Zhang, Jingwei;
Tao, Jianping;
Gong, Yu;
Mao, Jun;
Tian, Qixing;
Ao, Ping;
Zhuo, Dong

Publication type:

Article

Targeted PD-L1 PLGA/liposomes-mediated luteolin therapy for effective liver cancer cell treatment.

Published in:

Journal of Biomaterials Applications, 2021, v. 36, n. 5, p. 843, doi. 10.1177/08853282211017701

By:

Cao, Xinqiao;
Wang, Bing

Publication type:

Article

PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management.

Published in:

Archive of Clinical Cases, 2021, v. 8, n. 1, p. 14, doi. 10.22551/2021.30.0801.10179

By:

Bancu, Andrei;
Cowan, Richard;
Chaturvedi, Anshuman

Publication type:

Article

Fighting disease at 83 years old: SARS-CoV-2 survival and response to anti-PD-1 therapy in PD-L1 negative adenocarcinoma of the lung – case report.

Published in:

Oncolog-Hematolog, 2022, n. 58, p. 32

By:

Nedelcu Rezumat (Chiurciu), Maria;
Dragomir, Adelina Silvana;
Mateianu, Elena Adriana;
Stănculeanu, Dana Lucia

Publication type:

Article

Neoadjuvant treatment in triple-negative breast cancer.

Published in:

Oncolog-Hematolog, 2020, n. 52, p. 40

By:

Galeş, Laurenţia;
Bacinschi, Xenia;
Trifănescu, Oana;
Şerbănescu, Luiza;
Anghel, Rodica

Publication type:

Article

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors.

Published in:

Central European Journal of Immunology, 2024, v. 49, n. 2, p. 147, doi. 10.5114/ceji.2024.142418

By:

YANAN ZHAO;
DI WU;
QUANJUN YAO;
HANG YUAN;
HONGTAO HU;
HAILIANG LI

Publication type:

Article

An updated review of immunotherapy in esophageal cancer: PD-L1 footprint.

Published in:

Central European Journal of Immunology, 2024, v. 49, n. 1, p. 77, doi. 10.5114/ceji.2024.139269

By:

JUAN YAO;
XIAOYAN TAN;
YANPING SHA;
YURAO CHEN;
RONGHUAI CHEN;
DONGPING SHI

Publication type:

Article

Suppression of PD‐L1 release from small extracellular vesicles promotes systemic anti‐tumor immunity by targeting ORAI1 calcium channels.

Published in:

Journal of Extracellular Vesicles, 2022, v. 11, n. 12, p. 1, doi. 10.1002/jev2.12279

By:

Chen, Xi;
Li, Jiaqi;
Zhang, Ren;
Zhang, Yao;
Wang, Xiaoxuan;
Leung, Elaine Lai‐Han;
Ma, Lijuan;
Wong, Vincent Kam Wai;
Liu, Liang;
Neher, Erwin;
Yu, Haijie

Publication type:

Article

Binding of phosphatidylserine‐positive microparticles by PBMCs classifies disease severity in COVID‐19 patients.

Published in:

Journal of Extracellular Vesicles, 2021, v. 10, n. 14, p. 1, doi. 10.1002/jev2.12173

By:

Rausch, Lisa;
Lutz, Konstantin;
Schifferer, Martina;
Winheim, Elena;
Gruber, Rudi;
Oesterhaus, Elina F.;
Rinke, Linus;
Hellmuth, Johannes C.;
Scherer, Clemens;
Muenchhoff, Maximilian;
Mandel, Christopher;
Bergwelt‐Baildon, Michael;
Simons, Mikael;
Straub, Tobias;
Krug, Anne B.;
Kranich, Jan;
Brocker, Thomas

Publication type:

Article

WJMSC‐derived small extracellular vesicle enhance T cell suppression through PD‐L1.

Published in:

Journal of Extracellular Vesicles, 2021, v. 10, n. 4, p. 1, doi. 10.1002/jev2.12067

By:

Li, Meizhang;
Soder, Rupal;
Abhyankar, Sunil;
Abdelhakim, Haitham;
Braun, Mitchell W.;
Trinidad, Camille V.;
Pathak, Harsh B.;
Pessetto, Ziyan;
Deighan, Clayton;
Ganguly, Siddhartha;
Dawn, Buddhadeb;
McGuirk, Joseph;
Dunavin, Neil;
Godwin, Andrew K.

Publication type:

Article

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.

Published in:

Journal of Extracellular Vesicles, 2020, v. 9, n. 1, p. 1, doi. 10.1080/20013078.2019.1710899

By:

Cordonnier, Marine;
Nardin, Charlée;
Chanteloup, Gaëtan;
Derangere, Valentin;
Algros, Marie-Paule;
Arnould, Laurent;
Garrido, Carmen;
Aubin, François;
Gobbo, Jessica

Publication type:

Article

Exosomal PD-L1 functions as an immunosuppressant to promote wound healing.

Published in:

Journal of Extracellular Vesicles, 2020, v. 9, n. 1, p. 1, doi. 10.1080/20013078.2019.1709262

By:

Su, Dandan;
Tsai, Hsiang-I;
Xu, Zhanxue;
Yan, Fuxia;
Wu, Yingyi;
Xiao, Youmei;
Liu, Xiaoyan;
Wu, Yanping;
Parvanian, Sepideh;
Zhu, Wangshu;
Eriksson, John E.;
Wang, Dongqing;
Zhu, Haitao;
Chen, Hongbo;
Cheng, Fang

Publication type:

Article

Purity and yield of melanoma exosomes are dependent on isolation method.

Published in:

2020

By:

Shu, Shin La;
Yang, Yunchen;
Allen, Cheryl L.;
Hurley, Edward;
Tung, Kaity H.;
Minderman, Hans;
Wu, Yun;
Ernstoff, Marc S.

Publication type:

Report

Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients.

Published in:

Journal of Extracellular Vesicles, 2020, v. 9, n. 1, p. 1, doi. 10.1080/20013078.2019.1710899

By:

Cordonnier, Marine;
Nardin, Charlée;
Chanteloup, Gaëtan;
Derangere, Valentin;
Algros, Marie‐Paule;
Arnould, Laurent;
Garrido, Carmen;
Aubin, François;
Gobbo, Jessica

Publication type:

Article

Exosomal PD‐L1 functions as an immunosuppressant to promote wound healing.

Published in:

Journal of Extracellular Vesicles, 2020, v. 9, n. 1, p. 1, doi. 10.1080/20013078.2019.1709262

By:

Su, Dandan;
Tsai, Hsiang‐I;
Xu, Zhanxue;
Yan, Fuxia;
Wu, Yingyi;
Xiao, Youmei;
Liu, Xiaoyan;
Wu, Yanping;
Parvanian, Sepideh;
Zhu, Wangshu;
Eriksson, John E.;
Wang, Dongqing;
Zhu, Haitao;
Chen, Hongbo;
Cheng, Fang

Publication type:

Article

Purity and yield of melanoma exosomes are dependent on isolation method.

Published in:

Journal of Extracellular Vesicles, 2020, v. 9, n. 1, p. 1, doi. 10.1080/20013078.2019.1692401

By:

La Shu, Shin;
Yang, Yunchen;
Allen, Cheryl L.;
Hurley, Edward;
Tung, Kaity H.;
Minderman, Hans;
Wu, Yun;
Ernstoff, Marc S.

Publication type:

Article

Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma.

Published in:

eLife, 2024, p. 1, doi. 10.7554/eLife.90911

By:

Tiesuo Zhao;
Pengkun Wei;
Congli Zhang;
Shijie Zhou;
Lirui Liang;
Shuoshuo Guo;
Zhinan Yin;
Sichang Cheng;
Zerui Gan;
Yuanling Xia;
Yongxi Zhang;
Sheng Guo;
Jiateng Zhong;
Zishan Yang;
Fei Tu;
Qianqing Wang;
Jin Bai;
Feng Ren;
Zhiwei Feng;
Huijie Jia

Publication type:

Article

BMS‐202, a PD‐1/PD‐L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways.

Published in:

Immunity, Inflammation & Disease, 2022, v. 10, n. 10, p. 1, doi. 10.1002/iid3.693

By:

Cai, Yuanyuan;
Xiao, Min;
Li, Xinqing;
Zhou, Shanyu;
Sun, Yangyang;
Yu, Wenyuan;
Zhao, Tianlan

Publication type:

Article

Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors.

Published in:

Immunity, Inflammation & Disease, 2021, v. 9, n. 4, p. 1584, doi. 10.1002/iid3.511

By:

Miao Wang;
Hongchao Zhen;
Xiaoyue Jiang;
Yuting Lu;
Yuhan Wei;
Jiangtao Jin;
Qin Li

Publication type:

Article

Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade.

Published in:

Immunity, Inflammation & Disease, 2021, v. 9, n. 4, p. 1573, doi. 10.1002/iid3.510

By:

Otgontuya Ganbaatar;
Satoru Konnai;
Tomohiro Okagawa;
Yutaro Nojima;
Naoya Maekawa;
Yoshiki Ichikawa;
Atsushi Kobayashi;
Tomoyuki Shibahara;
Yojiro Yanagawa;
Hidetoshi Higuchi;
Yukinari Kato;
Yasuhiko Suzuki;
Shiro Murata;
Kazuhiko Ohashi

Publication type:

Article